A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 63
- Registration Number
- NCT06304103
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
- Conditions
- β -Thalassemia
- Interventions
- Drug: AND017 capsulesDrug: AND017 Placebo
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 64
- Registration Number
- NCT06302491
- Locations
- 🇨🇳
Liuzhou People's Hospital, Liuzhou, Guangxi, China
🇨🇳Nanfang Hospital Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Guangxi Medical University No.1 Affiliated Hospital, Nanning, Guangxi, China
A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06075043
A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06075030
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
- Conditions
- Renal Anemia
- Interventions
- Drug: AND017 capsules TIWDrug: AND017 capsules QW
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 175
- Registration Number
- NCT05265325
- Locations
- 🇺🇸
North America Research Institute, Riverside, California, United States
🇺🇸US Renal Care - Pine Bluff, Pine Bluff, Arkansas, United States
🇨🇳The Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- Drug: AND019 PO QD
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 61
- Registration Number
- NCT05187832
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 113
- Registration Number
- NCT05035641
- Locations
- 🇺🇸
Clinical Site Partners, Winter Park, Florida, United States
🇺🇸Amicis Research Center, Northridge, California, United States
🇺🇸Metrolina Nephrology Associates, Charlotte, North Carolina, United States
A Dose-escalation Study of AND017 in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- Drug: AND017 multiple doseDrug: PlaceboDrug: AND017 single dose
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 78
- Registration Number
- NCT04751539
- Locations
- 🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
A Food-Effect Study of AND017 in Healthy Participants
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Kind Pharmaceuticals LLC
- Target Recruit Count
- 14
- Registration Number
- NCT04712500
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China